The Expanding Role of the Advanced Practice Provider in National Cancer Institute Sponsored Trials

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP ¹, Marie Bakitas, DNSc, NP-C, FAAN², Lisa Kottschade, MS, APRN, CNP, FAPO³, Bridget O'Brien, DNP, FNP-BC, AOCNP ⁴, Marie Flannery, PhD, RN⁵, Alisha T. DeTroye, MMS, PA-C, DFAAPA ⁶, Al B. Benson III,MD, FACP, FACCC, FASCO ⁷, Marge J. Good, RN, MPH ⁸, Kathleen Castro, RN, MS, AOCN ⁸, Jamie Myers, PhD, RN, AOCNS, FAAN ⁹

Affiliations: ¹University of Hawaii Cancer Center, Honolulu, HI; ²Univeristy of Alabama, Birmingham, AL ³Mayo Clinic, Rochester, School of Nursing and URCC NCORP, Rochester, NY; ⁶ Atrium Health Wake Forest Baptist, Winston-Salem, NC, ⁷Northwestern Medicine, Chicago, IL, ⁸National Cancer Institute, Bethesda, MD, ⁹University of Kansas City, KS

Background:

- The National Cancer Institute (NCI) supports the largest United States network of clinical trials through two programs: National Clinical Trials Network (NCTN) & NCI Community Oncology Research Program (NCORP).
- NCI has removed barriers and changed policy and guidelines for APPs to have greater and more meaningful roles in NCI sponsored trials



As of Sept. 7th 2021: IND agents and standard of care agents, may be written by <u>qualified APPs without a physician co-signature</u>.

APPs must be registered with the NCI as Non-Physician Investigators (NPIVRs).

Qualified APPs may include: NPs, PAs, CNS, Pharmacists and Advanced Degree Nurses & be licensed and qualified per institutional policy, local and state laws and regulations.

NCORP protocols allow:

- APPs will be qualified to:
 - Serve as chairs (PhD only)
 - ❖Serve as co-chairs (PhD, DNP, PharmD, or Master's)
 - **❖**Serve as a local investigator to consent and enroll patients
 - Prescribe/write orders



Methods:

- Representatives within the NCI worked with APPs, Nurse Scientists and Physicians from research bases to advocate for changes in the NCI guidelines and polices
- The SWOG Cancer Nursing Research Sub-Committee and Palliative and End of Life Care Committee launched a five-year APP Engagement Project
- A working group with representation from the NCI and all of the NCTN/NCORP Research Bases was developed to support the APP initiative

Implications for Practice

- ✓ Policy and guideline changes permit APPs to participate consistent with their scope of practice
- ✓ Increased APP education and engagement with the NCTN/NCORP Network can increase accrual and improve conduct of clinical trials
- ✓ APPs can significantly contribute to protocol development and leadership in NCI sponsored research
- ✓ APPs involvement in clinical research provides patients with increased access to latest treatment options
- ✓ APPs involvement in clinical research provides opportunities to expand clinical skills, research expertise, professional development and career satisfaction

AUTHOR CONTACT INFORMATION


Christa M. Braun-Inglis, NP, University of Hawaii Cancer Center, CBraunInglis@cc.hawaii.edu

ACKNOWLEDGEMENTS

Funding: Supported by NIH/NCI grant award UG1CA189974, and with support from The Hope Foundation for Cancer Research.

Results:

- > 1,007 NPIVR's listed in NCORP-SYS as members of NCORP's (as of 4/1/22)
- More than 100 physicians, APPs, nurses and research professionals participated in the SWOG APP symposium in April 2022
- ➤ The University of Rochester Cancer Center Research Base NCORP led an APP-specific symposium in June of 2022 to highlight, facilitate and encourage APP leadership and participation in clinical trials



NCORP & Non-NCORP NPIVR Enrollments to NCORP Trials

	8/1/19 – 7/31/20	8/1/20 - 7/31/21	8/1/21 – 7/31/22
NCORP Clinical Trials			
NCORP Enrollments	0	458	648
Non-NCORP Enrollments	0	0	2
NCORP CCDR Studies	0	2	147
Total	0	460	797